|

LYL314 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Lyell Immunopharma, Inc.1

Indications

  • Large B-cell Lymphoma1
  • Refractory Non-Hodgkin Lymphoma1
  • Relapsed Non-Hodgkin Lymphoma1
  • Non-hodgkin Lymphoma1
  • Cancer1

Irvine, California1 trial

Study of LYL314 in Aggressive Large B-Cell Lymphoma

University of California-Irvine Medical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.